Nexalin Technology

Nexalin Technology Long-term Debt

The Long-Term Debt of Nexalin Technology (NXL) as of Oct 25, 2026 is 22,916.00 USD. In the previous year, Long-Term Debt was 52,305.00 USD — a change of -56.19% (lower).

Long-term Debt

22,916.00USD

YoY

-56.19%

Last updated:

Long-Term Debt of Nexalin Technology is 2021 22,916.00 USD. Long-Term Debt of Nexalin Technology was 2020 52,305.00 USD. It decreases by -56.19% lower compared to the previous year.

The Nexalin Technology Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2020
52,305.00 USD
Jan 1, 2021
22,916.00 USD
The Nexalin Technology Long-term Debt history
YEARLong-term DebtYoY
22,916.00USD-56.19%
52,305.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Long-Term Debt of Nexalin Technology is 22,916.00 USD in 2021.

Long-Term Debt of Nexalin Technology changed from 52,305.00 USD to 22,916.00 USD, representing a -56.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Nexalin Technology

All Key Metrics — Nexalin Technology